Full Comparison Table

FeatureSermorelinHGH (Somatropin)
MechanismGHRH(1-29) analog — stimulates pituitary GH releaseDirect GH replacement (191 AA somatropin)
Half-life~10–20 minutes (short; pulsatile release)~3–5 hours post-injection
Injection frequency3–7x per week (typically nightly)Daily (or 5-on-2-off)
IGF-1 EffectModerate; ceiling set by pituitary capacityStronger, more controllable; no natural ceiling
Pituitary EffectPreserves and "exercises" pituitary functionProgressive suppression of natural GH output
Supraphysiologic IGF-1 riskLow (feedback loop remains intact)Higher at doses above 1–2 IU/day
Cost/month~$150–$300 (compounded)$800–$2,000+ (US pharma); cheaper overseas
Legal statusPrescription required; compounded from licensed pharmacyPrescription required; Schedule III (US)
FDA historyFDA-approved (1997, pediatric GHD; discontinued commercially)FDA-approved for multiple indications
Best use caseAnti-aging; borderline-low IGF-1; pituitary-intact patientsDiagnosed GHD; depleted pituitary reserve; max IGF-1 needed

Understanding Sermorelin's Pituitary Preservation Advantage

Sermorelin's most cited advantage is that it preserves and stimulates the pituitary gland rather than replacing it. Physicians who prefer sermorelin often describe it as "exercising" the pituitary — regular GHRH stimulation maintains the pituitary's capacity to produce GH, which is particularly valuable in middle-aged patients whose GH output has declined but whose gland is still functional.

This mechanism also provides an inherent safety buffer: the pituitary's own somatostatin feedback prevents IGF-1 from rising above the physiological ceiling that your age and body can sustain. With exogenous HGH, there is no such automatic limit — IGF-1 can exceed the normal range if the dose is not carefully monitored, and persistently elevated supraphysiologic IGF-1 carries theoretical risks including cell proliferation associations.

The limitation: sermorelin's effectiveness is entirely dependent on pituitary reserve. In older patients (typically 70+) whose pituitary has significantly atrophied, the gland may not respond adequately to GHRH stimulation. In these cases, direct HGH replacement is the more appropriate clinical choice.

Who Should Choose Sermorelin?

  • Anti-aging and longevity seekers wanting a physiological, softer approach
  • Patients with low-normal or borderline-low IGF-1 and intact pituitary function
  • Those concerned about theoretical IGF-1 cancer risk from supraphysiologic levels
  • Budget-sensitive patients ($150–300/month vs $800–2,000+ for HGH)
  • Physicians who prefer preserving the patient's natural GH axis

Who Should Choose HGH?

  • Formally diagnosed adult GH deficiency (stimulation test confirmed)
  • Older patients (70+) with significantly depleted pituitary reserve
  • Patients who did not respond adequately to sermorelin or peptide stack therapy
  • Those requiring maximum, precisely controllable IGF-1 elevation
  • HIV wasting, short bowel syndrome, or other FDA-approved indications

Cost Breakdown: What You Actually Pay

For most patients pursuing GH therapy for anti-aging and longevity, cost is a deciding factor. Sermorelin wins decisively on affordability:

Sermorelin

  • Compounded pharmacy: ~$150–300/month
  • Includes: vials, bacteriostatic water, syringes
  • Prescription required from physician or clinic
  • Quality: Varies by compounding pharmacy — use 503B outsourcing facilities when possible

HGH (Somatropin)

  • US brand-name (Norditropin, Humatrope): $800–$2,000+/month
  • Omnitrope (biosimilar): $600–$1,400/month
  • With insurance for GHD diagnosis: Often covered; varies by plan
  • Overseas / compounded: Lower cost but significant quality and legal risks

Frequently Asked Questions

What is the main difference between sermorelin and HGH?

Sermorelin (GHRH 1-29) stimulates the pituitary to release its own GH — preserving the natural feedback loop. HGH (somatropin) is direct GH replacement that bypasses and progressively suppresses the pituitary. Sermorelin works with your axis; HGH replaces it.

Is sermorelin safer than HGH?

Sermorelin has a key safety advantage: the pituitary's own feedback prevents IGF-1 from rising to supraphysiologic levels. With HGH, there is no automatic ceiling — IGF-1 can exceed normal range without careful monitoring. Sermorelin is also less effective in patients with depleted pituitary reserve, where HGH is the better clinical choice.

How much cheaper is sermorelin than HGH?

Compounded sermorelin costs approximately $150–300/month. Branded HGH costs $800–$2,000+/month in the US. For comparable anti-aging applications (not diagnosed deficiency), sermorelin represents an 85–90% cost saving.

When is HGH preferred over sermorelin?

HGH is preferred for formally diagnosed adult GH deficiency (stimulation test confirmed), older patients with depleted pituitary reserve who do not respond to secretagogues, and cases where maximum controllable IGF-1 elevation is needed.

Track Sermorelin or HGH Free with Shotlee